Vivo Opportunity Fund Holdings Acquires 21.7% Stake in InMed Pharmaceuticals Amid Mentari Merger

On June 10, 2026, Vivo Opportunity Fund Holdings, L.P. and its affiliates filed a Schedule 13D disclosing a new 21.7% ownership stake in InMed Pharmaceuticals Inc. (INM). The reporting persons acquired 718,444 common shares through open market purchases between May 19, 2026, and June 8, 2026, following the announcement of a merger agreement between InMed and Mentari Therapeutics, Inc. Under the terms of the merger, InMed's subsidiary will merge with Mentari. Additionally, Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund executed a Securities Purchase Agreement with Mentari to participate in a pre-closing financing. Upon the closing of the merger, Mentari shares issued in this financing will convert into InMed common shares based on a specified exchange ratio. The reporting persons acquired the shares for investment purposes and currently hold significant voting and dispositive power over the issuer's securities. Additional affiliates, including Vivo Opportunity Cayman Fund, L.P., hold an additional 2.2% stake, bringing the collective interest in the issuer higher.